Skip to main content

Vanda, after rejecting Future Pak offer, gets $466M takeout bid from Cycle Pharma

Submitted by admin on
snippet

In recent months, Vanda Pharmaceuticals has been busy working to grow its commercial presence through its acquisition of Johnson & Johnson's Ponvory and its recent bipolar disorder approval for Fanapt. It seems the company's efforts are not going unnoticed.

Source
Fierce Pharma
Headline
Vanda, after rejecting Future Pak offer, gets $466M takeout bid from Cycle Phar…
News Tags
Vanda Pharmaceuticals
JNJ
M&A
Cycle Pharma
Future Pak
Fanapt

FDA approves Vanda's drug for treatment of bipolar disorder

Submitted by admin on
snippet

The U.S. FDA approved Vanda Pharmaceuticals' (VNDA.O) drug to treat manic and mixed episodes associated with a type of bipolar disorder, the company said on Tuesday, marking the second approval for the treatment.

Source
Reuters
Headline
FDA approves Vanda's drug for treatment of bipolar disorder
News Tags
Vanda Pharmaceuticals
bipolar disorder
FDA
Fanapt

FDA Grants Fanapt® Three Years of Marketing Exclusivity for Labeling Changes Relating to Maintenance Treatment of Schizophrenia

Submitted by admin on
Source
Yahoo
Headline
FDA Grants Fanapt® Three Years of Marketing Exclusivity for Labeling Changes Re…
News Tags
FDA
Fanapt
Vanda Pharmaceuticals
market exclusivity
schizophrenia
Subscribe to Fanapt